Director at Medicus Pharma (MDCX) receives grant of 50,000 stock options

Rhea-AI Filing Summary

Medicus Pharma Ltd. director May Sara R. received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. Following this grant, she holds options for 50,000 shares directly.

According to the terms, the option grant was made on June 3, 2026 and is scheduled to vest quarterly in four equal installments over one year. This is a compensation-related award, not an open-market purchase or sale of shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider May Sara R.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 50,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 50,000 options Exercise price: $0.36 per share Underlying shares: 50,000 common shares +3 more

6 metrics

Option grant size 50,000 options Stock Option (right to buy) granted June 3, 2026

Exercise price $0.36 per share Conversion or exercise price of stock option

Underlying shares 50,000 common shares Underlying security shares for the option grant

Expiration date June 3, 2031 Option expiration date for granted stock options

Post-grant derivative holdings 50,000 options Total derivative shares following transaction

Vesting schedule Quarterly over 1 year Four equal installments starting from June 3, 2026

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, derivative, exercise price, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

derivative financial

"transaction_type: derivative"

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

exercise price financial

"conversion_or_exercise_price: 0.3600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest quarterly financial

"The option is scheduled to vest quarterly in four equal installments"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

May Sara R.

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.36	06/03/2026		A		50,000		(1)	06/03/2031	Common Shares	50,000	$0	50,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for Sara R. May	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Medicus Pharma (MDCX) report for May Sara R.?

Medicus Pharma reported a stock option grant to director May Sara R. for 50,000 common shares. The options were awarded as compensation, not purchased on the market, and give her the right to buy shares at a fixed exercise price.

How many Medicus Pharma (MDCX) shares are covered by the new option grant?

The option grant covers the right to acquire 50,000 Medicus Pharma common shares. These options increase her derivative-based exposure to the company, with all 50,000 options shown as held directly after the reported transaction.

What is the exercise price of the Medicus Pharma (MDCX) options granted?

The granted stock options have an exercise price of $0.36 per share. This means May Sara R. can purchase Medicus Pharma common shares at $0.36 each once the options vest and as long as they are exercised before expiration.

When do the new Medicus Pharma (MDCX) stock options vest?

The options are scheduled to vest quarterly in four equal installments over one year starting from the June 3, 2026 grant date. This structure spreads vesting across the year rather than all options becoming exercisable immediately.

When do the Medicus Pharma (MDCX) options granted to May Sara R. expire?

The stock options expire on June 3, 2031. After this expiration date, any unexercised options can no longer be used to buy Medicus Pharma common shares, so exercise must occur on or before that date.

Is the Medicus Pharma (MDCX) Form 4 transaction a market buy or sell?

The Form 4 reports a grant, award, or other acquisition of stock options, not an open-market buy or sell. It reflects compensation received in the form of options rather than trading of existing Medicus Pharma common shares.